FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166116346> ?p ?o ?g. }

• W3166116346 endingPage "2633" @default.
• W3166116346 startingPage "2633" @default.
• W3166116346 abstract "2633 Background: Emerging data suggest that concomitant medications (CM) influence response to ICI. CM impact the host microbiome which may mitigate tumor-immune responsiveness. PPI use in patients treated with ICI has been associated with worse survival. Few data exist regarding the effects of PPI use in terms of prior chemotherapy or in risk for immune related adverse events (irAE) (e.g., colitis). Methods: This retrospective study of patients with advanced cancer treated with ICI between 2011 and 2019 was conducted at The Ohio State University. Patients who received ICI as either single agent or combination were included. Clinical data was abstracted from chart review, including CM, toxicity, and survival. Overall survival (OS) was evaluated to date of death or last contact. Associations between OS and proton pump inhibitor (PPI) use were studied using log-rank tests and Cox regression analyses overall and by the groups of whether prior chemotherapy was administered and timing from chemotherapy to ICI. The associations between PPI and incidence of irAE (overall and colitis) were assessed by chi-square tests. Results: We identified 1,091 patients treated with ICI, of whom 415 (38%) received PPI at time of ICI. Most common cancers were NSCLC and melanoma; most common therapy was PD1/L1 (Table). PPI use was associated with shorter OS in patients treated as first line therapy (HR = 1.46, 95% CI = [1.11, 1.91], p=0.006) and in second line and beyond (HR = 1.30, 95% CI = [1.10, 1.53], p=0.002). PPI use was associated with shorter OS in patients treated with ICI for those without prior chemotherapy (HR = 1.47, 95% CI = [1.17, 1.86], p=0.001). When evaluated by timing from chemotherapy to ICI, PPI use was associated with shorter OS only in patients where last chemotherapy was > 1 year from ICI (HR = 1.99, 95% CI [1.15, 3.45], p=0.014) but not for patients with chemotherapy within 1 year of ICI (HR = 1.01, 95% CI = [0.79, 1.29], p=0.960). The use of PPI was not associated with incidence of irAE (p=0.317) or colitis in particular (p=0.781). Conclusions: PPI use was associated with shorter survival in patients treated with ICI across a broad variety of cancers and in first line of therapy or beyond. In patients with recent chemotherapy (<1 year), PPI use was not associated with survival, which may be due to disruption of the microbiome by chemotherapy. Further study is needed to determine the impact of CM (e.g, PPI), on outcomes of patients treated with ICI.[Table: see text]" @default.
• W3166116346 created "2021-06-22" @default.
• W3166116346 creator A5004712121 @default.
• W3166116346 creator A5005703060 @default.
• W3166116346 creator A5006468163 @default.
• W3166116346 creator A5006900391 @default.
• W3166116346 creator A5022597516 @default.
• W3166116346 creator A5028643512 @default.
• W3166116346 creator A5029853460 @default.
• W3166116346 creator A5030801209 @default.
• W3166116346 creator A5035319531 @default.
• W3166116346 creator A5045110376 @default.
• W3166116346 creator A5048607187 @default.
• W3166116346 creator A5059760846 @default.
• W3166116346 creator A5059895822 @default.
• W3166116346 creator A5078163668 @default.
• W3166116346 creator A5078689933 @default.
• W3166116346 creator A5080186286 @default.
• W3166116346 creator A5084710012 @default.
• W3166116346 creator A5091280788 @default.
• W3166116346 date "2021-05-20" @default.
• W3166116346 modified "2023-10-13" @default.
• W3166116346 title "Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy." @default.
• W3166116346 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.2633" @default.
• W3166116346 hasPublicationYear "2021" @default.
• W3166116346 type Work @default.
• W3166116346 sameAs 3166116346 @default.
• W3166116346 citedByCount "5" @default.
• W3166116346 countsByYear W31661163462022 @default.
• W3166116346 countsByYear W31661163462023 @default.
• W3166116346 crossrefType "journal-article" @default.
• W3166116346 hasAuthorship W3166116346A5004712121 @default.
• W3166116346 hasAuthorship W3166116346A5005703060 @default.
• W3166116346 hasAuthorship W3166116346A5006468163 @default.
• W3166116346 hasAuthorship W3166116346A5006900391 @default.
• W3166116346 hasAuthorship W3166116346A5022597516 @default.
• W3166116346 hasAuthorship W3166116346A5028643512 @default.
• W3166116346 hasAuthorship W3166116346A5029853460 @default.
• W3166116346 hasAuthorship W3166116346A5030801209 @default.
• W3166116346 hasAuthorship W3166116346A5035319531 @default.
• W3166116346 hasAuthorship W3166116346A5045110376 @default.
• W3166116346 hasAuthorship W3166116346A5048607187 @default.
• W3166116346 hasAuthorship W3166116346A5059760846 @default.
• W3166116346 hasAuthorship W3166116346A5059895822 @default.
• W3166116346 hasAuthorship W3166116346A5078163668 @default.
• W3166116346 hasAuthorship W3166116346A5078689933 @default.
• W3166116346 hasAuthorship W3166116346A5080186286 @default.
• W3166116346 hasAuthorship W3166116346A5084710012 @default.
• W3166116346 hasAuthorship W3166116346A5091280788 @default.
• W3166116346 hasConcept C121608353 @default.
• W3166116346 hasConcept C126322002 @default.
• W3166116346 hasConcept C143998085 @default.
• W3166116346 hasConcept C197934379 @default.
• W3166116346 hasConcept C2776694085 @default.
• W3166116346 hasConcept C2779384505 @default.
• W3166116346 hasConcept C2781025758 @default.
• W3166116346 hasConcept C50382708 @default.
• W3166116346 hasConcept C71924100 @default.
• W3166116346 hasConcept C90924648 @default.
• W3166116346 hasConceptScore W3166116346C121608353 @default.
• W3166116346 hasConceptScore W3166116346C126322002 @default.
• W3166116346 hasConceptScore W3166116346C143998085 @default.
• W3166116346 hasConceptScore W3166116346C197934379 @default.
• W3166116346 hasConceptScore W3166116346C2776694085 @default.
• W3166116346 hasConceptScore W3166116346C2779384505 @default.
• W3166116346 hasConceptScore W3166116346C2781025758 @default.
• W3166116346 hasConceptScore W3166116346C50382708 @default.
• W3166116346 hasConceptScore W3166116346C71924100 @default.
• W3166116346 hasConceptScore W3166116346C90924648 @default.
• W3166116346 hasFunder F4320332161 @default.
• W3166116346 hasIssue "15_suppl" @default.
• W3166116346 hasLocation W31661163461 @default.
• W3166116346 hasOpenAccess W3166116346 @default.
• W3166116346 hasPrimaryLocation W31661163461 @default.
• W3166116346 hasRelatedWork W1517549033 @default.
• W3166116346 hasRelatedWork W2029518877 @default.
• W3166116346 hasRelatedWork W2088744974 @default.
• W3166116346 hasRelatedWork W2106653639 @default.
• W3166116346 hasRelatedWork W2146292537 @default.
• W3166116346 hasRelatedWork W2149063600 @default.
• W3166116346 hasRelatedWork W2361700749 @default.
• W3166116346 hasRelatedWork W2381345080 @default.
• W3166116346 hasRelatedWork W4248512896 @default.
• W3166116346 hasRelatedWork W1655344218 @default.
• W3166116346 hasVolume "39" @default.
• W3166116346 isParatext "false" @default.
• W3166116346 isRetracted "false" @default.
• W3166116346 magId "3166116346" @default.
• W3166116346 workType "article" @default.